miR-34a-Mediated Survivin Inhibition Improves the Antitumor Activity of Selinexor in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive disease with limited therapeutic options. Here, we pursued a combinatorial therapeutic approach to enhance the activity of selinexor, the first-in-class XPO1 inhibitor, by miR-34a ectopic expression in human TNBC experimental models. Anti-prolife...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Pharmaceuticals (Basel)
Main Authors: Martini, Silvia, Zuco, Valentina, Tortoreto, Monica, Percio, Stefano, Campi, Elisa, El Bezawy, Rihan, Doldi, Valentina, Landesman, Yosef, Pennati, Marzia, Zaffaroni, Nadia
Formato: Artigo
Idioma:Inglês
Publicado: MDPI 2021
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8227962/
https://ncbi.nlm.nih.gov/pubmed/34072442
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph14060523
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares